MUMBAI, India, April 10 -- Intellectual Property India has published a patent application (202411070777 A) filed by Fairbrook Group Limited; and Sundeep Aurora, Tortola, British Virgin Islands, on Sept. 19, 2024, for 'oral extended-release dosage form of 7- methylxanthine (7-mx) for the treatment of myopia.'
Inventor(s) include Sundeep Aurora; and Neha Aurora.
The application for the patent was published on April 10, under issue no. 15/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to an oral extended-release dosage form of 7-methylxanthine (7-MX) or a pharmaceutically acceptable salt thereof. The dosage form is designed for twice-daily administration and provides controlled release of the active agent, achieving pharmacokinetic characteristics including sustained plasma concentrations and reduced fluctuation compared to immediate-release formulations. The invention further relates to the use of such dosage forms in the treatment of myopia, wherein the extended-release characteristics enhance therapeutic effectiveness in myopia."
Disclaimer: Curated by HT Syndication.
